Home › Compare › RVVTF vs DIVO

RVVTF vs DIVO: Dividend Comparison 2026

RVVTF yields 7692.31% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVVTF wins by $4177739098279589.00M in total portfolio value
10 years
RVVTF
RVVTF
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full RVVTF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — RVVTF vs DIVO

📍 RVVTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVVTFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVVTF + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RVVTF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVVTF
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, RVVTF beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVVTF + DIVO for your $10,000?

RVVTF: 50%DIVO: 50%
100% DIVO50/50100% RVVTF
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVVTF buys
0
DIVO buys
0
No recent congressional trades found for RVVTF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVVTFDIVO
Forward yield7692.31% ✓6.49%
Annual dividend / share$2.00$2.91 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4177739098279589.00M ✓$30.7K
Annual income after 10y$4,073,565,928,588,968,500,000.00 ✓$981.68
Total dividends collected$4170772265337663.00M ✓$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RVVTF vs DIVO ($10,000, DRIP)

YearRVVTF PortfolioRVVTF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$779,931$769,230.77$11,349$649.42+$768.6K → RVVTF
2$56,904,315$56,069,789.30$12,833$688.83+$56.89M → RVVTF
3$3,884,151,673$3,823,264,055.84$14,459$727.90+$3884.14M → RVVTF
4$248,050,254,929$243,894,212,638.74$16,238$766.49+$248050.24M → RVVTF
5$14,822,056,221,428$14,556,642,448,653.80$18,179$804.47+$14822056.20M → RVVTF
6$828,776,618,419,079$812,917,018,262,150.50$20,293$841.71+$828776618.40M → RVVTF
7$43,367,472,132,823,630$42,480,681,151,115,220.00$22,591$878.14+$43367472132.80M → RVVTF
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$25,087$913.65+$2123871047251.57M → RVVTF
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$27,791$948.18+$97358102514598.28M → RVVTF
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$30,718$981.68+$4177739098279589.00M → RVVTF

RVVTF vs DIVO: Complete Analysis 2026

RVVTF — Stock

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Full RVVTF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this RVVTF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVVTF vs SCHDRVVTF vs JEPIRVVTF vs ORVVTF vs KORVVTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.